Insys Theraptcs Cmn (INSY) 14.36 $INSY Insys

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 7:11 AM

Insys Theraptcs Cmn (INSY) 14.36 $INSY

Insys Therapeutics, Inc. to Present at Morgan Stanley Global Healthcare Conference
GlobeNewswire - Thu Sep 01, 6:00AM CDT
Insys Therapeutics, Inc. ("Insys" or "the Company"

(NASDAQ:INSY) today announced that Darryl Baker, Chief Financial Officer, and Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, will present at the Morgan Stanley Global Healthcare Conference as follows:
INSY: 14.36 (+0.09), MS: 31.91 (-0.15)

Purcell Julie & Lefkowitz LLP Is Investigating Insys Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Tue Aug 30, 7:07AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Insys Therapeutics, Inc. (NASDAQ: INSY).
INSY: 14.36 (+0.09)

Covered Call reports for Fitbit, INSYS Therapeutics, eBay, Morgan Stanley and Cisco Systems include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Aug 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CSCO, EBAY, FIT, INSY, and MS.
FIT: 14.95 (-0.53), INSY: 14.36 (+0.09), EBAY: 32.13 (-0.03), CSCO: 31.58 (+0.14), MS: 31.91 (-0.15)

Insys Therapeutics Reports Phase 3 Trial of Sublingual Buprenorphine Spray Met Primary Endpoint in Patients with Moderate-to-Severe Postoperative Pain after Bunionectomy
GlobeNewswire - Wed Aug 24, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company"

today reported that the Phase 3 trial for the Buprenorphine Sublingual Spray met its primary endpoint.
INSY: 14.36 (+0.09)

Insys Therapeutics Starts Enrollment in Cannabidiol Trial
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 4:32PM CDT
Insys Therapeutics, Inc. (INSY) announced that it has enrolled the first patient in a phase II trial on its pharmaceutical cannabidiol (CBD) product candidate.
INSY: 14.36 (+0.09), GWPH: 82.28 (+0.53), CORT: 5.35 (+0.02), PCRX: 40.37 (+0.74)

Identifying Newest Cannabis Strains for Cancer Treatment and Other Ailments Gain Headway Behind Pharmacological Evaluations
PR Newswire Europe - Wed Aug 10, 7:31AM CDT
CORAL SPRINGS, Florida, August 10, 2016 /PRNewswire/ --
ABT: 42.30 (+0.28), INSY: 14.36 (+0.09), CGC.TO: 3.77 (+0.06), GWPH: 82.28 (+0.53)

Insys Therapeutics Reports Second Quarter 2016 Results
GlobeNewswire - Wed Aug 03, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company"

today announced financial results for the three-month period ended June 30, 2016.
INSY: 14.36 (+0.09)

Medical Product Stocks Earnings Preview for Aug 3: BIO, CSII & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:35AM CDT
Medical has been a stand out performer so far in Q2.
MGNX: 30.05 (+0.24), INSY: 14.36 (+0.09), CSII: 24.45 (-0.02), BIO: 149.49 (+0.68), CNAT: 1.86 (+0.05)

What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.45 (+0.01), INSY: 14.36 (+0.09), AGIO: 36.74 (-0.10), GNCA: 5.28 (-0.08)

Insys Therapeutics, Inc. to Present at Two Upcoming Conferences in June
GlobeNewswire - Thu May 26, 3:30PM CDT
Insys Therapeutics, Inc. ("Insys" or "the Company"

(NASDAQ:INSY) today announced that Darryl Baker, Chief Financial Officer, and Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, will present at two upcoming conferences in June as follows:
INSY: 14.36 (+0.09)

By 2020 Marijuana Sales are Expected to Reach Nearly $23 Billion With Predictions 2016 Will Be the Greenest Year in History; Company Executes International License Agreement
PR Newswire - Wed May 25, 7:30AM CDT
As illustrated by the Spring 2016 Marijuana Business Conference & Expo earlier this month, the numbers and momentum of cannabis in the US are undeniable. As revenues continue to climb into the billions, more research and development push the sector forward.According to the newly released 4th Edition State of Legal Marijuana Markets Report from from ArcView Market Research and New Frontier, a cannabis-focused data-analysis firm, much of the increase in sector is attributed to adult use market sales, which hit $1.3 billion last year alone. By 2020, adult use and medical marijuana sales are expected to reach nearly $23 billion.
INSY: 14.36 (+0.09), GWPH: 82.28 (+0.53)

Insys Therapeutics Successfully Completes Safety and Pharmacokinetic (PK) Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients
GlobeNewswire - Tue May 24, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company"

today announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy.
INSY: 14.36 (+0.09)

Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board
GlobeNewswire - Mon May 16, 3:00PM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will serve as Chairman of the Board.
INSY: 14.36 (+0.09), RPRX: 2.00 (-0.03)

Insys Therapeutics beats Street 1Q forecasts
Automated Insights - Thu Apr 28, 9:36AM CDT
CHANDLER, Ariz. (AP) _ Insys Therapeutics Inc. (INSY) on Thursday reported first-quarter net income of $2.4 million.
INSY: 14.36 (+0.09)

Insys Therapeutics Reports First Quarter 2016 Results
GlobeNewswire - Thu Apr 28, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company"

today announced financial results for the three-month period ended March 31, 2016.
INSY: 14.36 (+0.09)

Insys Therapeutics, Inc. to Present at Deutsche Bank 41st Annual Health Care Conference
GlobeNewswire - Tue Apr 26, 3:30PM CDT
Insys Therapeutics, Inc. ("Insys" or "the Company"

(NASDAQ:INSY) today announced that Darryl Baker, Chief Financial Officer, and Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, will present at the Deutsche Bank 41 Annual Health Care Conference as follows:
INSY: 14.36 (+0.09), DB: 14.69 (-0.06)

Don't Get Smoked by These Pot Stocks on 4/20
David Bartosiak - Zacks Investment Research - Wed Apr 20, 3:45PM CDT
Pot is still illegal at the Federal level but there are some medicinal marijuana companies worth looking at
CARA: 5.38 (-0.04), JNJ: 119.08 (-0.26), INSY: 14.36 (+0.09), GWPH: 82.28 (+0.53), YUM: 90.76 (+0.05), PEP: 107.29 (+0.54)

What Falling Estimates & Price Mean for INSYS Therapeutics (INSY)
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 4:59PM CDT
INSYS Therapeutics has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
INSY: 14.36 (+0.09), ATRC: 15.50 (+0.11)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Minerva Foods' Profit Struggles Despite Revenue Growth

Setting the Stage: Minerva Foods' Latest Report Walking through the jungle of financial statements, few things are clear-cut. Minerva Foods handed out its latest report, stirring both optimism and concern among the suits at the table. Here's the brass tacks of it: a 9.5% boost in net revenue drumming up R$56.2 billion over twelve months. Sounds solid, huh? Yet, lurking...

Flagship, Gates Join Forces on Global Health Front

Pioneering Change in Global Health Here’s a collaboration that’s got science enthusiasts pinning it to their bulletin boards. Flagship Pioneering, a big name in crafting trailblazing scientific innovations, has linked arms with the Gates Foundation. They're pooling a cool $25 million to uncover game-changers in health and agriculture aimed squarely at underserved...

SoLo Alpha: Transforming Retail Investment Returns

Pushing Beyond Traditional Financial Constructs In a world where the average Joe is often left holding the short end of the investment stick, SoLo Funds comes charging through with SoLo Alpha, touting a whopping 16% annualized return. They're riding a wave of what seems like a financial revolution, serving up high returns usually reserved for the big fish. It’s hard not...

Trusted Space Joins Forces with Falcon ExoDynamics

Revolutionizing Space Autonomy with a Strategic Acquisition Sometimes, the stars align, and you've got a game-changer in the space domain. That's exactly what's cooking with Trusted Space's acquisition of Falcon ExoDynamics. What we're witnessing here is not just a merger—it's a seismic shift in how national security is handled in space. Autonomy: The Backbone of Modern...

Corgi Insurance Bolsters Specialty Lines with Tamez Hire

Corgi Insurance Welcomes Eric Tamez Out of the blue, they just dropped this little nugget—Eric Tamez is stepping into the Vice President shoes of Specialty Lines over at Corgi Insurance. If you're wondering, this isn't some run-of-the-mill appointment. We're talking about a guy who's been deep into the underbelly of the insurance beast, carving out a name in the mess of...

Surgery Partners and ADT Sales Under Legal Scrutiny

Shareholder Scrutiny on Mergers It's no secret that corporate mergers often kick up a fuss, but when insiders get a juicy payday while regular shareholders play catch-up, folks raise eyebrows. Halper Sadeh LLC, that gutsy law firm, isn't shy about going after possible dirty deals, and they've got their eyes on a few names related to potential securities law violations and...

Oxford Computer Group: A Microsoft Awards Finalist Again

Oxford Computer Group Strikes Again Another day, another nod from the big boys at Microsoft, eh? Oxford Computer Group, now part of MajorKey Technologies, hasn't just found themselves in the mix—they're standing tall as a finalist for not one but two significant categories in the 2026 Microsoft Partner of the Year Awards: Secure Access and Defense and Intelligence. You...

Claus for a Cause: Respecting Heroes with Holiday Cheer

An Unforgettable Holiday Season Veterans Day isn't just a date on the calendar—it's an opportunity to pause and offer genuine thanks to those who've served with honor. This year, as the holiday season rolls around, Gemmy Industries' Claus for a Cause collection is redefining how we show our appreciation. These aren't your ordinary inflatables; they come with a purpose...

Bit Digital Shifts Focus: Q3 2026 Sees Strategic Moves

Bit Digital's Strategic Shakeup Ah, the digital gold rush is heating up again. Bit Digital, the outfit focused on Ethereum strategies and AI, dropped their financial results for Q3 2026. Picture a company at a strategic crossroads, shedding bitcoin mining baggage to grab hold of fresh opportunities in Ethereum staking and AI infrastructure. Bit Digital's earnings paint a...

Piedmont Orthopedics Expands With Spine Expert

New Talent Joins OrthoAtlanta When a spine surgeon like Dr. Avionna L. Baldwin Jefferson heads to a practice, it becomes the kind of news that ripples through both local and medical communities. Piedmont Orthopedics | OrthoAtlanta has pulled a real coup, drawing in this fellowship-trained whiz with a sharp eye for minimally invasive procedures, craning necks in Covington,...